View Financial HealthLobe Sciences 배당 및 자사주 매입배당 기준 점검 0/6Lobe Sciences 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-1.0%자사주 매입 수익률총 주주 수익률-1.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Apr 21Lobe Sciences Ltd. announced that it has received CAD 0.95 million in fundingOn April 20, 2026, Lobe Sciences Ltd. has closed the transaction.공지 • Apr 08Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026.공지 • Jan 14Lobe Sciences Ltd Appoints Mr. Nick Karakochuk to Board of DirectorsLobe Sciences Ltd. announced the appointment of Mr. Nick Karakochuk to its Board of Directors as the Company continues to build on the momentum established during fiscal 2025. Mr. Karakochuk is a corporate and securities lawyer at DuMoulin Black LLP, where his practice focuses on mergers and acquisitions, public and private financing, corporate reorganizations, and governance matters. He regularly advises public and private issuers on stock exchange requirements, securities regulatory compliance, and continuous disclosure obligations, and has extensive experience supporting companies through complex transactions and strategic growth initiatives.공지 • Sep 10Lobe Sciences Ltd. Appoints Mr. Marco Mastrodonato to the Company's Board of DirectorsLobe Sciences Ltd. announced the appointment of Mr. Marco Mastrodonato to the Company's Board of Directors. Mr. Mastrodonato brings extensive leadership and international business development experience in the pharmaceutical and biotechnology industries. He was the former Co-Founder and Executive Director of Sinclair Pharma plc., a publicly listed pharmaceutical company on the London Stock Exchange. He founded and served as a Board Member of Metrodora Therapeutics Inc.; a U.S. biotechnology company focused on systemic inflammation and the treatment of anemia. Mr. Mastrodonato is also the Founder and CEO of BMG Pharma, where he leads the development and global commercialization of innovative hyaluronic acid-based technologies across aesthetic dermatology. ophthalmology and osteoarthritis.공지 • Jul 29Lobe Sciences Ltd. announced that it expects to receive CAD 0.341425 million in fundingLobe Sciences Ltd announced a non brokered private placement to issue 8,535,625 common shares at an issue price of CAD 0.04 for the proceeds of CAD 341,425 on July 29, 2025. All securities to be issued pursuant to the offering will be subject to a statutory four-month-and-one-day hold period.공지 • Jan 15Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025.공지 • Nov 19Lobe Sciences Ltd. and Alera Pharma, Inc. Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™Lobe Sciences Ltd. and Alera Pharma Inc. announced that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof. This application contains claims covering compositions comprising a psilocin mucate salt or conjugate and methods for their production and use in conditions treatable with psilocin.공지 • Aug 16Lobe Sciences, Ltd Announces Management Appointments to Alera Pharma, IncLobe Sciences Ltd. ("Lobe Sciences" or the "Company") announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera.공지 • Aug 13+ 1 more updateLobe Sciences Ltd Announces CEO ChangesLobe Sciences Ltd. has appointed Dr. Frederick D. Sancilio as Chief Executive Officer of the Company. The Board announces resignations of CEO Philip Young.공지 • Jun 06+ 1 more updateLobe Sciences Ltd. announced that it has received CAD 0.5 million in funding from Quality Chemical Laboratories, LLC, Clearway Global LlcLobe Sciences Ltd. announced a private placement of a convertible note for the gross proceeds of CAD 500,000 on June 4, 2024. The transaction included participation from new investors, Quality Chemical Laboratories, LLC and Clearway Global Llc.공지 • Jun 01Lobe Sciences Ltd. Announces Frederick D. Sancilio Ph.D. to Join Board of DirectorsLobe Sciences Ltd. announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors. Dr. Sancilio brings over four decades of successful experience in pharmaceutical sciences and biopharmaceutical research, further strengthening Lobe Sciences' commitment to pioneering advancements in mental health and wellness. Dr. Sancilio completed his B.S., M.S., and Ph.D. in Physical and Analytical Chemistry at Rutgers, The State University of New Jersey. His career has been marked by significant achievements, including founding aaiPharma Inc., where he led the company to become the world's dosage form development company with over 1,000 US FDA and 500 European drug approvals. Dr. Sancilio has a proven track record of driving growth and innovation, having founded multiple successful pharmaceutical companies and contributed to the biopharmaceutical industry's development in North Carolina. As a serial entrepreneur Dr. Sancilio is largely responsible for helping to define the modern Contract Research and Development Organization marketplace with the founding of aaiPharma Inc. which focused on providing drug product development services to both entrepreneurial and established pharmaceutical companies. The company became a NASDAQ publicly traded company in 1996 and grew to a market capitalization of nearly $1BB by 2001. Dr. Sancilio retired from aaiPharma in June 2002. The company was reorganized in 2005, privatized and renamed Alcami Inc., and continues to dominate its business segment. Following his retirement as CEO of aaiPharma in 2002, Dr. Sancilio established a family office in Jupiter, Florida and affiliated with several investment and merchant banks in South Florida including Comvest Partners and the Noble Capital Markets. In 2007, he founded Sancilio & Company Inc. (SCI), a specialty pharmaceutical company located in Palm Beach County, Florida. SCI’s primary focus was to develop drug products for diseases with unmet medical needs. The Company’s 150,000 square foot facility in Riviera Beach, Fl was approved as a drug manufacturing site by the US FDA in 2017 and received its first prescription drug approval in that facility in early 2018 making it the first US FDA approval of a drug product in Palm Beach County in over 2 decades. Facilities, products and intellectual property were acquired in early 2018 and are now operated by Procaps Group SA, a NASDAQ listed Company. In early January 2018, Dr. Sancilio and his wife Carolyn Sancilio founded Clearway Global Inc., a consulting and product development company that is wholly owned by Sancilio & Company, located in Stuart, Fl. He continues to do research and development work in sickle cell disease, broad spectrum anti-viral drugs and neurological disorders including Alzheimer’s Disease, substance abuse and addiction. He is also involved in guiding the development of several new drug candidates for Clearway Global’s international client companies where he serves in a variety of positions. In July 2019, Dr. Sancilio accepted a position as a Research Professor and Managing Director, Translational Development & Commercialization in the Division of Research at Florida Atlantic University, Boca Raton, Fl and continues as a Research Professor in the Department of Chemistry and Biochemistry.공지 • May 31Harry Jacobson to Join the Board of Directors of Lobe Sciences LtdLobe Sciences Ltd. announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months. Dr. Jacobson brings over three decades of distinguished experience in healthcare, biotechnology, and medical innovation. As a serial entrepreneur, executive and visionary leader, his extensive knowledge and strategic insights will be invaluable to Lobe Sciences as the company continues to pioneer treatments and expand its footprint in the development of transformative medicines for orphan and rare diseases. Board certified in Internal Medicine and Nephrology, Dr. Jacobson joined Vanderbilt Medical Faculty in 1985 as Professor of Medicine and Director of the Division of Nephrology. After developing one of the nation’s premier nephrology divisions, Dr. Jacobson was named Vice Chancellor for Health Affairs and CEO of the Vanderbilt University Medical Center (VUMC). As Vice Chancellor for Health Affairs, Dr. Jacobson’s 12-year tenure saw the VUMC budget expand from $750M to $2.5B, all the while delivering superior care. Vanderbilt’s federally funded research moved from 24th to top 10 in the country and more than $1B of newly constructed facilities were opened. Among these projects are the Monroe Carell Children’s Hospital and Vanderbilt Health at 100 Oaks. During the course of his career, Dr. Jacobson has been a successful investor and entrepreneur, having founded or co-founded several companies, including Contact Software, the developer of the software program ACT which helped launch the CRM software category; Renal Care Group; Cardiovascular Care Group; Informatics Corporation of America; CeloNova Biosciences, Ambulatory Services of America; MindCare Solutions; Innovative Renal Care; MedLogic, and For Better Health (4BH). He has served on the boards of three New York Stock Exchange companies including Merck, Kinetic Concepts, and Renal Care Group. Currently, Dr. Jacobson serves on the Board of Directors of several healthcare companies from the original MedCare portfolio. In 2013, Dr. Jacobson served Belmont’s Jack C. Massey Graduate School of Business as its Distinguished Healthcare Executive-in-Residence and was Chairman of the McWhorter Society from 2014 to 2017.공지 • May 17Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024. Location: british columbia, vancouver Canada공지 • Dec 07Lobe Sciences Ltd. Provides Update on L-130 Clinical ProgramLobe Sciences Ltd. provided an update from the Company's lead clinical program, L-130, a proprietary stabilized psilocin conjjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects were evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. All subjects were dosed with no significant adverse events. The study confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable, capsule over its active prodrug, psilocybin. The mean maximum plasma concentration (Cmax) for L-130 was significantly higher than expected, demonstrating superior bioavailability compared to published literature of psilocybin. Additionally, time to achieve the maximum plasma concentration (Tmax) was lower for L-130 due to elimination of first-pass metabolism and immediate absorption in the gut. Full results are expected to be published in peer reviewed journals in the first half of 2024. Collectively, the superior pharmacokinetics of L- 130 offers significant therapeutic advantages over other psilocybin formulations as psilocybin itself is not biologically active in humans and must be converted into psilocin via dephosphorylation in the gut. By eliminating this first pass metabolism, industry experts believe the direct administration of psilocin may offer therapeutic benefits such as faster onset time, improved dosing consistency, increased bioavailability and importantly, the potential for reduced side effects.공지 • Sep 19Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial OfficerLobe Sciences Ltd. that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023. Mathew has over 15 years of experience as a finance executive. Mathew currently serves as president of Manning Lee Management Ltd., a management consulting firm providing CFO services to publicly traded companies. Mathew specializes in providing M&A, accounting, management, securities regulatory compliance, and corporate secretarial services to companies listed on the TSX-V, CSE, and OTC. Mathew is a CPA Charterholder and earned a B.Comm from the University of British Columbia.공지 • Jun 28Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130Lobe Sciences Ltd. announced the initiation of a Phase 1, pharmacokinetic clinical study of L-130, a proprietary stabilized psilocin analogue drug candidate in healthy volunteers. The first-in-man, open-label study, conducted in Jordan under the authority of the Jordan Food and Drug Administration, will help determine the dose range of L-130 for a planned Phase 2 trial targeting the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs). The Phase 1 study, conducted in compliance with the GCP and GLP regulatory requirements of the Declaration of Helsinki and the US FDA Guidelines for Bioavailability & Bioequivalence Studies, is an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects will be evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. To date, all subjects have been dosed with no significant adverse events. Full completion of the study is expected in Third Quarter 2023 and results will be used to determine L-130 dose levels for a planned Phase 2a study in chronic cluster headaches. Often said to be the most painful of all headaches, cluster headaches are a primary headache disorder and the most common of the group of headache disorders called trigeminal autonomic cephalalgias. The term cluster headaches comes from the fact that these attacks occur in groups, or "clusters." During a cluster cycle, brief, exceptionally severe headache attacks recur between 1-8 times per day. Cluster cycles can last for weeks or months and are usually separated by remission periods, or periods of headache freedom, which usually last months or years. People who experience chronic cluster headache have no remission periods, or the remissions last less than a month at a time.공지 • Jun 08Lobe Sciences Appoints Baxter Phillips as Chief Operating OfficerLobe Sciences Ltd. announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately. The position was created to provide additional executive leadership as Lobe Sciences continues its strategic transition to a diversified, fully integrated biopharmaceutical company preparing to launch its first commercial product, Altemia™, a medical food designed for patients with sickle cell anemia. Mr. Phillips will also serve as President, Altemia and Company, LLC, a Lobe Sciences wholly owned subsidiary focused on treatments and support for patients with sickle cell anemia. Phillips will report directly to Chairman and Chief Executive Officer Philip J. Young. In October of 2022, Mr. Phillips was appointed to Lobe Sciences' Board of Directors, where he will also continue to serve the Company. For the past 10 years of his 25 year career, Baxter has served as an executive officer, including CEO, of several multi-national biopharmaceutical companies including Cambridge Allergy (UK), Neurogastrx (US) and Armata Pharma (AmpliPhi, multi-national). Mr. Phillips has a successful history of acquiring and launching commercial products, leading multiple public and private financing campaigns, establishing cGMP manufacturing, and licensing product portfolios of commercial and development-stage programs. Mr. Phillips began his career as a research scientist with Insmed (INSM) where for ten years he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing. He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 LOBE.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: LOBE.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Lobe Sciences 배당 수익률 vs 시장LOBE.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (LOBE.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.2%분석가 예측 (LOBE.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 LOBE.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 LOBE.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 LOBE.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: LOBE.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 15:03종가2026/05/07 00:00수익2026/02/28연간 수익2025/08/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Lobe Sciences Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공지 • Apr 21Lobe Sciences Ltd. announced that it has received CAD 0.95 million in fundingOn April 20, 2026, Lobe Sciences Ltd. has closed the transaction.
공지 • Apr 08Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026Lobe Sciences Ltd., Annual General Meeting, Jun 15, 2026.
공지 • Jan 14Lobe Sciences Ltd Appoints Mr. Nick Karakochuk to Board of DirectorsLobe Sciences Ltd. announced the appointment of Mr. Nick Karakochuk to its Board of Directors as the Company continues to build on the momentum established during fiscal 2025. Mr. Karakochuk is a corporate and securities lawyer at DuMoulin Black LLP, where his practice focuses on mergers and acquisitions, public and private financing, corporate reorganizations, and governance matters. He regularly advises public and private issuers on stock exchange requirements, securities regulatory compliance, and continuous disclosure obligations, and has extensive experience supporting companies through complex transactions and strategic growth initiatives.
공지 • Sep 10Lobe Sciences Ltd. Appoints Mr. Marco Mastrodonato to the Company's Board of DirectorsLobe Sciences Ltd. announced the appointment of Mr. Marco Mastrodonato to the Company's Board of Directors. Mr. Mastrodonato brings extensive leadership and international business development experience in the pharmaceutical and biotechnology industries. He was the former Co-Founder and Executive Director of Sinclair Pharma plc., a publicly listed pharmaceutical company on the London Stock Exchange. He founded and served as a Board Member of Metrodora Therapeutics Inc.; a U.S. biotechnology company focused on systemic inflammation and the treatment of anemia. Mr. Mastrodonato is also the Founder and CEO of BMG Pharma, where he leads the development and global commercialization of innovative hyaluronic acid-based technologies across aesthetic dermatology. ophthalmology and osteoarthritis.
공지 • Jul 29Lobe Sciences Ltd. announced that it expects to receive CAD 0.341425 million in fundingLobe Sciences Ltd announced a non brokered private placement to issue 8,535,625 common shares at an issue price of CAD 0.04 for the proceeds of CAD 341,425 on July 29, 2025. All securities to be issued pursuant to the offering will be subject to a statutory four-month-and-one-day hold period.
공지 • Jan 15Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025Lobe Sciences Ltd., Annual General Meeting, Mar 20, 2025.
공지 • Nov 19Lobe Sciences Ltd. and Alera Pharma, Inc. Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™Lobe Sciences Ltd. and Alera Pharma Inc. announced that a second patent allowance for Conjugated Psilocin™ has been received. The patent application is entitled Stable Psilocin Salts, Esters, and Conjugates and Uses Thereof. This application contains claims covering compositions comprising a psilocin mucate salt or conjugate and methods for their production and use in conditions treatable with psilocin.
공지 • Aug 16Lobe Sciences, Ltd Announces Management Appointments to Alera Pharma, IncLobe Sciences Ltd. ("Lobe Sciences" or the "Company") announced that is has formed a wholly owned U.S. subsidiary named Alera Pharma Inc. (Alera). Alera will be assigned the intellectual property rights focused on the Company’s neurological assets and its new chemical entity Psilocin Mucate. Mr. Rick Goulburn has been appointed as the Chief Executive Officer of Alera. Dr. Fred D. Sancilio will be Chairman of its Board of Directors and be joined on the board by Dr. Harry Jacobson, Mr. Wesley Ramjeet and Mr. Goulburn. Alera will be the operating company within the Lobe Sciences group focused on neurology and will join Altemia, LLC as the second operating subsidiary of Lobe Sciences. It is expected that the Company’s Australian subsidiary, Lobe Sciences Australia Pty Ltd., will become a subsidiary of Alera. Mr. Ilan Hayman will become a member of the executive management team of Alera.
공지 • Aug 13+ 1 more updateLobe Sciences Ltd Announces CEO ChangesLobe Sciences Ltd. has appointed Dr. Frederick D. Sancilio as Chief Executive Officer of the Company. The Board announces resignations of CEO Philip Young.
공지 • Jun 06+ 1 more updateLobe Sciences Ltd. announced that it has received CAD 0.5 million in funding from Quality Chemical Laboratories, LLC, Clearway Global LlcLobe Sciences Ltd. announced a private placement of a convertible note for the gross proceeds of CAD 500,000 on June 4, 2024. The transaction included participation from new investors, Quality Chemical Laboratories, LLC and Clearway Global Llc.
공지 • Jun 01Lobe Sciences Ltd. Announces Frederick D. Sancilio Ph.D. to Join Board of DirectorsLobe Sciences Ltd. announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors. Dr. Sancilio brings over four decades of successful experience in pharmaceutical sciences and biopharmaceutical research, further strengthening Lobe Sciences' commitment to pioneering advancements in mental health and wellness. Dr. Sancilio completed his B.S., M.S., and Ph.D. in Physical and Analytical Chemistry at Rutgers, The State University of New Jersey. His career has been marked by significant achievements, including founding aaiPharma Inc., where he led the company to become the world's dosage form development company with over 1,000 US FDA and 500 European drug approvals. Dr. Sancilio has a proven track record of driving growth and innovation, having founded multiple successful pharmaceutical companies and contributed to the biopharmaceutical industry's development in North Carolina. As a serial entrepreneur Dr. Sancilio is largely responsible for helping to define the modern Contract Research and Development Organization marketplace with the founding of aaiPharma Inc. which focused on providing drug product development services to both entrepreneurial and established pharmaceutical companies. The company became a NASDAQ publicly traded company in 1996 and grew to a market capitalization of nearly $1BB by 2001. Dr. Sancilio retired from aaiPharma in June 2002. The company was reorganized in 2005, privatized and renamed Alcami Inc., and continues to dominate its business segment. Following his retirement as CEO of aaiPharma in 2002, Dr. Sancilio established a family office in Jupiter, Florida and affiliated with several investment and merchant banks in South Florida including Comvest Partners and the Noble Capital Markets. In 2007, he founded Sancilio & Company Inc. (SCI), a specialty pharmaceutical company located in Palm Beach County, Florida. SCI’s primary focus was to develop drug products for diseases with unmet medical needs. The Company’s 150,000 square foot facility in Riviera Beach, Fl was approved as a drug manufacturing site by the US FDA in 2017 and received its first prescription drug approval in that facility in early 2018 making it the first US FDA approval of a drug product in Palm Beach County in over 2 decades. Facilities, products and intellectual property were acquired in early 2018 and are now operated by Procaps Group SA, a NASDAQ listed Company. In early January 2018, Dr. Sancilio and his wife Carolyn Sancilio founded Clearway Global Inc., a consulting and product development company that is wholly owned by Sancilio & Company, located in Stuart, Fl. He continues to do research and development work in sickle cell disease, broad spectrum anti-viral drugs and neurological disorders including Alzheimer’s Disease, substance abuse and addiction. He is also involved in guiding the development of several new drug candidates for Clearway Global’s international client companies where he serves in a variety of positions. In July 2019, Dr. Sancilio accepted a position as a Research Professor and Managing Director, Translational Development & Commercialization in the Division of Research at Florida Atlantic University, Boca Raton, Fl and continues as a Research Professor in the Department of Chemistry and Biochemistry.
공지 • May 31Harry Jacobson to Join the Board of Directors of Lobe Sciences LtdLobe Sciences Ltd. announced that Dr. Harry Jacobson has agreed to join its Board of Directors in the coming months. Dr. Jacobson brings over three decades of distinguished experience in healthcare, biotechnology, and medical innovation. As a serial entrepreneur, executive and visionary leader, his extensive knowledge and strategic insights will be invaluable to Lobe Sciences as the company continues to pioneer treatments and expand its footprint in the development of transformative medicines for orphan and rare diseases. Board certified in Internal Medicine and Nephrology, Dr. Jacobson joined Vanderbilt Medical Faculty in 1985 as Professor of Medicine and Director of the Division of Nephrology. After developing one of the nation’s premier nephrology divisions, Dr. Jacobson was named Vice Chancellor for Health Affairs and CEO of the Vanderbilt University Medical Center (VUMC). As Vice Chancellor for Health Affairs, Dr. Jacobson’s 12-year tenure saw the VUMC budget expand from $750M to $2.5B, all the while delivering superior care. Vanderbilt’s federally funded research moved from 24th to top 10 in the country and more than $1B of newly constructed facilities were opened. Among these projects are the Monroe Carell Children’s Hospital and Vanderbilt Health at 100 Oaks. During the course of his career, Dr. Jacobson has been a successful investor and entrepreneur, having founded or co-founded several companies, including Contact Software, the developer of the software program ACT which helped launch the CRM software category; Renal Care Group; Cardiovascular Care Group; Informatics Corporation of America; CeloNova Biosciences, Ambulatory Services of America; MindCare Solutions; Innovative Renal Care; MedLogic, and For Better Health (4BH). He has served on the boards of three New York Stock Exchange companies including Merck, Kinetic Concepts, and Renal Care Group. Currently, Dr. Jacobson serves on the Board of Directors of several healthcare companies from the original MedCare portfolio. In 2013, Dr. Jacobson served Belmont’s Jack C. Massey Graduate School of Business as its Distinguished Healthcare Executive-in-Residence and was Chairman of the McWhorter Society from 2014 to 2017.
공지 • May 17Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024Lobe Sciences Ltd., Annual General Meeting, Jul 22, 2024. Location: british columbia, vancouver Canada
공지 • Dec 07Lobe Sciences Ltd. Provides Update on L-130 Clinical ProgramLobe Sciences Ltd. provided an update from the Company's lead clinical program, L-130, a proprietary stabilized psilocin conjjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects were evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. All subjects were dosed with no significant adverse events. The study confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable, capsule over its active prodrug, psilocybin. The mean maximum plasma concentration (Cmax) for L-130 was significantly higher than expected, demonstrating superior bioavailability compared to published literature of psilocybin. Additionally, time to achieve the maximum plasma concentration (Tmax) was lower for L-130 due to elimination of first-pass metabolism and immediate absorption in the gut. Full results are expected to be published in peer reviewed journals in the first half of 2024. Collectively, the superior pharmacokinetics of L- 130 offers significant therapeutic advantages over other psilocybin formulations as psilocybin itself is not biologically active in humans and must be converted into psilocin via dephosphorylation in the gut. By eliminating this first pass metabolism, industry experts believe the direct administration of psilocin may offer therapeutic benefits such as faster onset time, improved dosing consistency, increased bioavailability and importantly, the potential for reduced side effects.
공지 • Sep 19Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial OfficerLobe Sciences Ltd. that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023. Mathew has over 15 years of experience as a finance executive. Mathew currently serves as president of Manning Lee Management Ltd., a management consulting firm providing CFO services to publicly traded companies. Mathew specializes in providing M&A, accounting, management, securities regulatory compliance, and corporate secretarial services to companies listed on the TSX-V, CSE, and OTC. Mathew is a CPA Charterholder and earned a B.Comm from the University of British Columbia.
공지 • Jun 28Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130Lobe Sciences Ltd. announced the initiation of a Phase 1, pharmacokinetic clinical study of L-130, a proprietary stabilized psilocin analogue drug candidate in healthy volunteers. The first-in-man, open-label study, conducted in Jordan under the authority of the Jordan Food and Drug Administration, will help determine the dose range of L-130 for a planned Phase 2 trial targeting the treatment of chronic cluster headaches (CCH), the most predominant headache disorder within the group of trigeminal autonomic cephalgias (TACs). The Phase 1 study, conducted in compliance with the GCP and GLP regulatory requirements of the Declaration of Helsinki and the US FDA Guidelines for Bioavailability & Bioequivalence Studies, is an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmacokinetic parameters of L-130 after a single oral dose. All subjects will be evaluated for impacts on cognition and anxiolytic effects on day 1, 7 and 28. To date, all subjects have been dosed with no significant adverse events. Full completion of the study is expected in Third Quarter 2023 and results will be used to determine L-130 dose levels for a planned Phase 2a study in chronic cluster headaches. Often said to be the most painful of all headaches, cluster headaches are a primary headache disorder and the most common of the group of headache disorders called trigeminal autonomic cephalalgias. The term cluster headaches comes from the fact that these attacks occur in groups, or "clusters." During a cluster cycle, brief, exceptionally severe headache attacks recur between 1-8 times per day. Cluster cycles can last for weeks or months and are usually separated by remission periods, or periods of headache freedom, which usually last months or years. People who experience chronic cluster headache have no remission periods, or the remissions last less than a month at a time.
공지 • Jun 08Lobe Sciences Appoints Baxter Phillips as Chief Operating OfficerLobe Sciences Ltd. announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO) effective immediately. The position was created to provide additional executive leadership as Lobe Sciences continues its strategic transition to a diversified, fully integrated biopharmaceutical company preparing to launch its first commercial product, Altemia™, a medical food designed for patients with sickle cell anemia. Mr. Phillips will also serve as President, Altemia and Company, LLC, a Lobe Sciences wholly owned subsidiary focused on treatments and support for patients with sickle cell anemia. Phillips will report directly to Chairman and Chief Executive Officer Philip J. Young. In October of 2022, Mr. Phillips was appointed to Lobe Sciences' Board of Directors, where he will also continue to serve the Company. For the past 10 years of his 25 year career, Baxter has served as an executive officer, including CEO, of several multi-national biopharmaceutical companies including Cambridge Allergy (UK), Neurogastrx (US) and Armata Pharma (AmpliPhi, multi-national). Mr. Phillips has a successful history of acquiring and launching commercial products, leading multiple public and private financing campaigns, establishing cGMP manufacturing, and licensing product portfolios of commercial and development-stage programs. Mr. Phillips began his career as a research scientist with Insmed (INSM) where for ten years he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing. He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.